Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

• Autors principals: Richard B. Warren (Autor), Lev Pavlovsky (Autor), Antonio Costanzo (Autor), Michael Bukhalo (Autor), Neil J. Korman (Autor), Yu-Huei Huang (Autor), Georgios Kokolakis (Autor), Andreas Pinter (Autor), Nadia Ibrahim (Autor), Yanbing Zheng (Autor), Leonidas Drogaris (Autor), Vassilis Stakias (Autor), Ahmed M. Soliman (Autor), Simone Rubant (Autor), Diamant Thaçi (Autor)
• Format: Llibre
• Publicat: Adis, Springer Healthcare, 2024-11-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Abstract Introduction Risankizumab has demonstrated superior efficacy compared to other psoriasis treatments, including secukinumab, adalimumab, and ustekinumab; switching to risankizumab from other psoriasis treatments has shown superior clinical and quality of life (QoL) outcomes. We evaluated the...